

## Correction: *Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds*

van Diest E, Hernández López P, Meringa AD, *et al.* Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. *J Immunother Cancer* 2021;**9**:e003850. doi:10.1136/jitc-2021-003850.

This article has been corrected since it was first published. The Abstract section has now been added.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2021;**9**:e003850corr1. doi:10.1136/jitc-2021-003850corr1

